|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2012
|
|
gptkbp:ATCCode
|
gptkb:R07AX02
|
|
gptkbp:availableOn
|
worldwide
|
|
gptkbp:brand
|
gptkb:Kalydeco
|
|
gptkbp:CASNumber
|
873054-44-5
|
|
gptkbp:chemicalClass
|
quinoline derivative
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to ivacaftor
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:drugInteraction
|
CYP3A inducers
CYP3A inhibitors
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:form
|
gptkb:tablet
granules
|
|
gptkbp:hasMolecularFormula
|
C24H28N2O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ivacaftor
|
|
gptkbp:indication
|
gptkb:G551D_mutation_in_CFTR
|
|
gptkbp:KEGGID
|
D09716
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
CFTR potentiator
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
392.49 g/mol
|
|
gptkbp:patent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
16220172
DB08820
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
headache
rash
upper respiratory tract infection
|
|
gptkbp:synonym
|
gptkb:VX-770
|
|
gptkbp:target
|
gptkb:CFTR_protein
|
|
gptkbp:UNII
|
6S6HT6E8TV
|
|
gptkbp:usedFor
|
cystic fibrosis
|
|
gptkbp:bfsParent
|
gptkb:CFTR_gene
gptkb:CFTR_modulators
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Symdeko
gptkb:Trikafta
|
|
gptkbp:bfsLayer
|
6
|